Abstract: The use of blue light cystoscopy (BLC) has been shown to improve bladder tumor detection. However, data demonstrating the efficacy of BLC across different races are limited. Herein, we aim to evaluate heterogeneity in the characteristics of BLC for the detection of malignant lesions among various races. Clinicopathologic information was collected from patients enrolled in the multi-institutional Cysview® registry (2014–2021) who underwent transurethral resection or biopsy of bladder tumors. Outcome variables included sensitivity and negative and positive predictive values of BLC and white light cystoscopy (WLC) for the detection of malignant lesions among various races. Overall, 2379 separate lesions/tumors were identified from 1292 patients, of whom 1095 (85%) were Caucasian, 96 (7%) were African American, 51 (4%) were Asian, and 50 (4%) were Hispanic. The sensitivity of BLC was higher than that of WLC in the total cohort, as well as in the Caucasian and Asian subgroups. The addition of BLC to WLC increased the detection rate by 10% for any malignant lesion in the total cohort, with the greatest increase in Asian patients (18%). Additionally, the positive predictive value of BLC was highest in Asian patients (94%), while Hispanic patients had the highest negative predictive value (86%). Our study showed that regardless of race, BLC increases the detection of bladder cancer when combined with WLC.
Seyedeh-Sanam Ladi-Seyedian,1 Alireza Ghoreifi,1 Badrinath Konety,2 Kamal Pohar,3 Jeffrey M. Holzbeierlein,4 John Taylor,4 Max Kates,5 Brian Willard,6 Jennifer M. Taylor,7 Joseph C. Liao,8 Hristos Z. Kaimakliotis,9 Sima P. Porten,10 Gary D. Steinberg,11 Mark D. Tyson,12 Yair Lotan,13 Siamak Daneshmand,1* and the Blue Light Cystoscopy with Cysview Registry Group
- Department of Urology, Norris Cancer Center, University of Southern California, Los Angeles, CA 90033, USA
- Allina Health Cancer Institute, Minneapolis, MN 55407, USA
- Department of Urology, Ohio State University, Columbus, OH 43210, USA
- Department of Urology, University of Kansas, Kansas City, KS 66045, USA
- The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21224, USA
- Lexington Medical Center, Lexington, SC 29169, USA
- Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX 77030, USA
- VA Palo Alto Health Care System, Palo Alto, CA 94304, USA
- Department of Urology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
- Department of Urology, University of California San Francisco, San Francisco, CA 94115, USA
- Department of Urology, University of Minnesota and Allina Health Cancer Institute, Minneapolis, MN 55407, USA
- Department of Urology, Mayo Clinic Hospital, Phoenix, AZ 85054, USA
- UT Southwestern Medical Center, Dallas, TX 75390, USA
Related content: Racial Differences in Bladder Cancer Detection Using Blue Light Cystoscopy: A Multi-Center Study - Siamak Daneshmand